Suven Life Sciences is a biopharmaceutical Company with 22 years of experience in discovering and developing novel pharmaceutical products, for CNS disorders. Our focus is targeting disease areas with unmet treatment opportunities. Suven singularly focuses on the development of “New Chemical Entities” (“NCEs”) molecules for CNS diseases such as Alzheimer’s disease, various forms of Dementia, Narcolepsy, Major Depressive Disorder (“MDD”), Parkinson's disease, Bipolar disorder, and different forms of neuropsychiatry disorders, and pain disorders.

•   Masupirdine (SUVN-502; 5-HT6 receptor antagonist): The most advanced clinical candidate. A global Phase-3 clinical trial to evaluate the potential of masupirdine for the treatment of agitation in Alzheimer’s disease patients is in progress.

•   Samelisant (SUVN-G3031; Histamine H3 receptor inverse agonist): Efficacy and safety of samelisant has been established in narcolepsy patients in a Phase-2 proof-of-concept (POC) study. Suven is planning to initiate the Phase-3 study to confirm the efficacy and safety.

•   Ropanicant (SUVN-911; α4β2 nAChR ligand): Ropanicant has shown robust efficacy in various animal models of depression. A Phase-2a clinical trial for the treatment of moderate to severe MDD is ongoing in the USA.

•   Usmarapride (SUVN-D4010; 5-HT4 receptor partial agonist): It shows robust efficacy in animal models of cognition and depression. A Phase-2 POC study evaluating the potential utility of Usmarapride in cognitive deficits is being planned.

-   In addition, 3 compounds are in the early stages of clinical development.

Visit our website : www.suven.com